PROCEPT BioRobotics Completes Enrollment in Key Prostate Cancer Study, Gains FDA Approval for New Trial
Summary
PROCEPT BioRobotics has completed enrollment for its WATER IV RP study, which compares Aquablation therapy to radical prostatectomy for prostate cancer. This is a significant milestone for the company's expansion into the prostate cancer market beyond its current BPH focus. Additionally, the company received FDA IDE approval for a second WATER IV AS study, evaluating Aquablation therapy against active surveillance for lower-risk prostate cancer. While primary endpoint results for the WATER IV RP study are expected in spring 2027, these advancements position the company for potential long-term growth in a larger addressable market.
At the time of this announcement, PRCT was trading at $26.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $19.35 to $66.85. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.